Published in

Taylor and Francis Group, Expert Opinion on Biological Therapy, 12(22), p. 1579-1584, 2022

DOI: 10.1080/14712598.2022.2070428

Links

Tools

Export citation

Search in Google Scholar

Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis

Journal article published in 2022 by Paolo Gisondi ORCID, Davide Geat, Patrizio Armeni, Francesco Bellinato ORCID, Martina Maurelli ORCID, Giampiero Girolomoni ORCID
Distributing this paper is prohibited by the publisher
Distributing this paper is prohibited by the publisher

Full text: Unavailable

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO